Platelet activating factor (PAF) and activity of its biosynthetic and catabolic enzymes in blood and leukocytes of male patients with newly diagnosed heart failure.

[1]  T. Tzotzas,et al.  Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women. , 2008, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[2]  C. Stefanadis,et al.  Serum uric acid levels correlate with left atrial function and systolic right ventricular function in patients with newly diagnosed heart failure: the hellenic heart failure study. , 2008, Congestive heart failure.

[3]  G. Ma,et al.  Relationship between CD40 ligand expression and B type natriuretic peptide levels in patients with chronic heart failure. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[4]  G. Lip,et al.  Relationship of soluble CD40 ligand to vascular endothelial growth factor, angiopoietins, and tissue factor in atrial fibrillation: a link among platelet activation, angiogenesis, and thrombosis? , 2007, Chest.

[5]  G. Camussi,et al.  The Proangiogenic Phenotype of Tumor-Derived Endothelial Cells is Reverted by the Overexpression of Platelet-Activating Factor Acetylhydrolase , 2007, Clinical Cancer Research.

[6]  S. Tsimikas,et al.  In Atherosclerosis and Cardiovascular Disease 2 Phospholipase a New Insights into the Role of Lipoprotein(a)-associated Lipoprotein-associated , 2022 .

[7]  T. Nomikos,et al.  Characterization of the De Novo Biosynthetic Enzyme of Platelet Activating Factor, DDT-Insensitive Cholinephosphotransferase, of Human Mesangial Cells , 2007, Mediators of inflammation.

[8]  T. Ueland,et al.  Role of inflammation in the progression of heart failure , 2007, Current cardiology reports.

[9]  K. Yee,et al.  Effect of spironolactone on C-reactive protein levels in patients with heart disease. , 2007, International journal of cardiology.

[10]  R. Wilensky,et al.  Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. , 2007, Atherosclerosis.

[11]  P. Box.  Lipoprotein-associated phospholipase A2 activity and risk of heart failure: The Rotterdam study , 2007 .

[12]  N. Andrikopoulos,et al.  A simple and precise method for the routine determination of platelet-activating factor in blood and urine , 1994, Lipids.

[13]  G. Vercellotti,et al.  Calcium channel blockade inhibits platelet activating factor production by human umbilical vein endothelial cells , 1991, Lipids.

[14]  K. Dickstein,et al.  Soluble CD40 ligand in acute and chronic heart failure. , 2005, European heart journal.

[15]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[16]  A. Matsumori.  Anti-inflammatory therapy for heart failure. , 2004, Current opinion in pharmacology.

[17]  G. Camussi,et al.  Platelet-Activating Factor Mediates CD40-Dependent Angiogenesis and Endothelial-Smooth Muscle Cell Interaction 1 , 2003, The Journal of Immunology.

[18]  Smaragdi Antonopoulou,et al.  Platelet activating factor — a molecular link between atherosclerosis theories , 2003 .

[19]  T. Nomikos,et al.  Acetyl-CoA:1-O-alkyl-sn-glycero-3-phosphocholine acetyltransferase (lyso-PAF AT) activity in cortical and medullary human renal tissue. , 2003, European journal of biochemistry.

[20]  G. Zimmerman,et al.  Platelet-Activating Factor, a Pleiotrophic Mediator of Physiological and Pathological Processes , 2003, Critical reviews in clinical laboratory sciences.

[21]  S. Silver,et al.  Heart Failure , 1937, The New England journal of medicine.

[22]  A. Nixon,et al.  Regulation of platelet-activating factor synthesis in human neutrophils by MAP kinases. , 2002, Biochimica et biophysica acta.

[23]  G. Camussi,et al.  Expression of CD154 on renal cell carcinomas and effect on cell proliferation, motility and platelet‐activating factor synthesis , 2002, International journal of cancer.

[24]  J. Prandota.  Furosemide: Progress in Understanding Its Diuretic, Anti-inflammatory, and Bronchodilating Mechanism of Action, and Use in the Treatment of Respiratory Tract Diseases , 2002, American journal of therapeutics.

[25]  J. Goudevenos,et al.  Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. , 2002, Journal of lipid research.

[26]  P. Bernatchez,et al.  Regulation of VEGF‐induced endothelial cell PAF synthesis: role of p42/44 MAPK, p38 MAPK and PI3K pathways , 2001, British journal of pharmacology.

[27]  G. Camussi,et al.  Role of platelet-activating factor in cardiovascular pathophysiology. , 2000, Physiological reviews.

[28]  P. Poole‐Wilson,et al.  Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. , 1997, The American journal of cardiology.

[29]  K. Kitamura,et al.  Platelet‐activating factor and arachidonic acid metabolites in psoriatic inflammation , 1996, The British journal of dermatology.

[30]  Queen Elizabeth.  Lyso-PAF acetyltransferase activity in neutrophils of patients during acute asthma and after recovery , 1996 .

[31]  F. Snyder,et al.  Platelet-activating factor and its analogs: metabolic pathways and related intracellular processes. , 1995, Biochimica et biophysica acta.

[32]  A. Mantovani,et al.  Synthesis of platelet-activating factor by polymorphonuclear neutrophils stimulated with interleukin-8. , 1992, The Journal of biological chemistry.

[33]  R. Heller,et al.  Nitrovasodilators inhibit thrombin-induced platelet-activating factor synthesis in human endothelial cells. , 1992, Biochemical pharmacology.

[34]  G. Camussi,et al.  Selected cytokines promote the synthesis of platelet-activating factor in vascular endothelial cells: comparison between tumor necrosis factor alpha and beta and interleukin-1. , 1990, Journal of lipid mediators.

[35]  L. Epstein,et al.  Biphasic platelet-activating factor synthesis by human monocytes stimulated with IL-1-beta, tumor necrosis factor, or IFN-gamma. , 1988, Journal of immunology.

[36]  H. White,et al.  Inhibition of lyso-PAF: acetyl-CoA acetyltransferase by salicylates and other compounds. , 1988, Prostaglandins.

[37]  M. Sánchez Crespo,et al.  Biosynthesis of platelet-activating factor in human polymorphonuclear leukocytes. Involvement of the cholinephosphotransferase pathway in response to the phorbol esters. , 1988, The Journal of biological chemistry.

[38]  D. Stafforini,et al.  Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. , 1987, The Journal of biological chemistry.

[39]  C. Vigo.  Effect of C-reactive protein on platelet-activating factor-induced platelet aggregation and membrane stabilization. , 1985, The Journal of biological chemistry.

[40]  D. Lenihan,et al.  Increased biosynthesis of platelet-activating factor in activated human eosinophils. , 1984, The Journal of biological chemistry.

[41]  D. Hanahan,et al.  Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). , 1979, The Journal of biological chemistry.

[42]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[43]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.